Clipper (beclomethasone): Uses, Dosage & Side Effects

What it's for (Indications)

Beclomethasone, as an inhaled corticosteroid (ICS), is primarily indicated for the maintenance treatment of asthma in adults and pediatric patients aged 5 years and older.
It serves as a prophylactic therapy to control the persistent inflammatory processes underlying asthma, thereby reducing the frequency and severity of asthma exacerbations and improving lung function.
It is crucial to emphasize that beclomethasone is not intended for the rapid relief of acute bronchospasm or for patients requiring immediate bronchodilation; rather, it is a controller medication that must be used regularly on a long-term basis to achieve its therapeutic benefits.
While other formulations (e.
g.
, nasal spray) are indicated for conditions like allergic rhinitis, the example provided, 'Clenil For Aerosol,' primarily targets the respiratory system for chronic asthma management.
Its therapeutic role is to manage underlying chronic inflammation, thereby preventing symptoms, rather than to alleviate acute respiratory distress.

Dosage Information

Type	Guideline
Standard	The dosage of beclomethasone, typically administered via a metered-dose inhaler (MDI), must be individualized based on the patient's age, disease severity, and previous response to corticosteroid therapy. For adults and adolescents, a common starting dose may range from 100 to 400 micrograms (mcg) twice daily, depending on the specific product formulation (e.g., HFA vs. older CFC propellants often have different potencies and delivery characteristics). Pediatric dosing, generally for children aged 5-11 years, often starts at lower ranges, such as 50 to 100 mcg twice daily. The dose should be carefully titrated to the lowest effective amount necessary to maintain asthma control, and treatment should be consistent, even during symptom-free periods. Patients must be instructed on proper inhaler technique, including the use of a spacer device, especially for younger children or those with difficulty coordinating inhalation, to maximize drug delivery to the lungs and minimize local side effects. It is vital to remind patients that this medication is a preventive measure and not for acute relief; a short-acting beta-agonist is required for immediate symptomatic relief.

Type

Guideline

Standard

The dosage of beclomethasone, typically administered via a metered-dose inhaler (MDI), must be individualized based on the patient's age, disease severity, and previous response to corticosteroid therapy. For adults and adolescents, a common starting dose may range from 100 to 400 micrograms (mcg) twice daily, depending on the specific product formulation (e.g., HFA vs. older CFC propellants often have different potencies and delivery characteristics). Pediatric dosing, generally for children aged 5-11 years, often starts at lower ranges, such as 50 to 100 mcg twice daily. The dose should be carefully titrated to the lowest effective amount necessary to maintain asthma control, and treatment should be consistent, even during symptom-free periods. Patients must be instructed on proper inhaler technique, including the use of a spacer device, especially for younger children or those with difficulty coordinating inhalation, to maximize drug delivery to the lungs and minimize local side effects. It is vital to remind patients that this medication is a preventive measure and not for acute relief; a short-acting beta-agonist is required for immediate symptomatic relief.

Safety & Warnings

Common Side Effects

While generally well-tolerated when used as directed, beclomethasone can cause a range of side effects, primarily localized to the oropharynx due to the direct deposition of the drug.
Common local adverse effects include oral candidiasis (thrush), characterized by white patches in the mouth or throat, dysphonia (hoarseness), cough, and throat irritation.
These can often be mitigated by rinsing the mouth and gargling with water after each use and by utilizing a spacer device.
Systemic side effects are less common with inhaled corticosteroids compared to oral formulations due to lower systemic absorption, but they can occur, especially at higher doses or with prolonged use.
These potential systemic effects may include adrenal suppression, a decrease in bone mineral density, growth suppression in children, posterior subcapsular cataracts, glaucoma, and an increased risk of infections such as pneumonia.
Patients should report any persistent or worsening symptoms to their healthcare provider.
Rare but serious side effects can include paradoxical bronchospasm, requiring immediate discontinuation, and hypersensitivity reactions such as rash, urticaria, angioedema, and bronchospasm.

Serious Warnings

Black Box Warning: Serious Warnings: Beclomethasone is an inhaled corticosteroid primarily indicated for the maintenance treatment of asthma as prophylactic therapy and is not intended for the relief of acute bronchospasm. Patients must be advised that this medication will not provide immediate relief during an acute asthma attack, and a fast-acting bronchodilator should be used for such episodes. Prolonged use of beclomethasone, particularly at higher doses, may lead to systemic corticosteroid effects, including hypothalamic-pituitary-adrenal (HPA) axis suppression. This can result in adrenal insufficiency, especially during periods of stress or abrupt discontinuation. Careful monitoring and gradual withdrawal are crucial in such cases. Patients may also experience increased susceptibility to infections due to the immunosuppressive effects of corticosteroids, including oral candidiasis (thrush), which can be minimized by rinsing the mouth after use. Long-term use in children may affect growth velocity, and regular monitoring of growth is recommended. Furthermore, potential ocular effects such as glaucoma and cataracts, and systemic effects on bone mineral density, should be considered with chronic administration. Paradoxical bronchospasm, though rare, can occur immediately after inhalation, requiring discontinuation of the drug and alternative therapy.
Beclomethasone is not indicated for the rapid relief of acute bronchospasm or status asthmaticus; patients must be clearly advised to use a rapid-acting beta-agonist for acute symptoms.
Caution is warranted in patients transitioning from systemic corticosteroids to inhaled beclomethasone, as adrenal suppression may persist for several months, necessitating careful monitoring and supplemental systemic corticosteroids during periods of stress or severe asthma attacks.
Due to its immunosuppressive effects, beclomethasone should be used with caution in patients with active or quiescent tuberculosis, ocular herpes simplex, or untreated systemic fungal, bacterial, viral, or parasitic infections, as it may exacerbate these conditions.
Long-term use of inhaled corticosteroids, particularly at high doses, may lead to a reduction in bone mineral density; patient risk factors for osteoporosis should be assessed.
Monitoring of growth in pediatric patients receiving inhaled corticosteroids is recommended.
The development of cataracts or glaucoma is a potential risk with long-term use, warranting regular ophthalmic examinations for at-risk patients.
Patients should be instructed to rinse their mouth after use to minimize the risk of oral candidiasis.
Abrupt discontinuation of beclomethasone, particularly after prolonged use at high doses, should be avoided due to the risk of precipitating adrenal insufficiency.

How it Works (Mechanism of Action)

Beclomethasone dipropionate is a synthetic corticosteroid and a prodrug. Upon inhalation, it is rapidly hydrolyzed in the lungs to its primary active metabolite, beclomethasone-17-monopropionate (B-17-MP), which exhibits potent anti-inflammatory activity. The mechanism of action primarily involves binding to intracellular glucocorticoid receptors within target cells of the airway (e.g., epithelial cells, mast cells, eosinophils, lymphocytes, macrophages). This binding initiates a cascade of genomic and non-genomic effects. Specifically, beclomethasone-17-monopropionate modulates gene expression, upregulating the synthesis of anti-inflammatory proteins (e.g., lipocortin-1) and downregulating the production of pro-inflammatory mediators such as cytokines (e.g., IL-1, IL-6, TNF-alpha), chemokines, prostaglandins, and leukotrienes. It also inhibits the migration and activity of inflammatory cells into the airways, reduces vascular permeability, and decreases mucus secretion. The cumulative effect of these actions is a profound reduction in airway inflammation, swelling, and hyperresponsiveness, leading to improved lung function, decreased asthma symptoms, and a reduction in the frequency and severity of asthma exacerbations. The local delivery to the respiratory tract maximizes therapeutic effects while minimizing systemic exposure and associated side effects, distinguishing it from systemic corticosteroids.